John Bradley Sorenson, Executive Vice President of Global Operations at Boston Scientific Corp (NYSE:BSX), recently sold a significant portion of company stock. According to a filing with the Securities and Exchange Commission,

Stifel raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares after having hosted

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher.

Truist Securities expressed a positive outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $120 from $110, while reaffirming a Buy rating. The stock, currently trading near its 52-week high of $107.

Barclays raised the firm’s price target on Boston Scientific (BSX) to $118 from $111 and keeps an Overweight rating on the shares. The firm